Affordable Access

Access to the full text

A Global Phase I Clinical Study Comparing the Safety and Pharmacokinetics of Proposed Biosimilar BAT1706 and Bevacizumab (Avastin®) in Healthy Male Subjects

Authors
  • Wu, Xiaoyun1
  • Wynne, Chris2
  • Xu, Chenchao1
  • Gan, Yiting1
  • Wang, Chaohe1
  • Thomas, Bert E.1
  • Yu, Jin-Chen1
  • Li, Shengfeng1
  • Zhang, Li1
  • 1 Bio-Thera Solutions, Ltd., Guangzhou, China , Guangzhou (China)
  • 2 Christchurch Clinical Studies Trust Ltd (CCST), Christchurch, New Zealand , Christchurch (New Zealand)
Type
Published Article
Journal
BioDrugs
Publisher
Springer International Publishing
Publication Date
Apr 23, 2019
Volume
33
Issue
3
Pages
335–342
Identifiers
DOI: 10.1007/s40259-019-00352-7
Source
Springer Nature
License
Yellow

Abstract

ObjectiveBAT1706 is a proposed biosimilar of bevacizumab (BEV). The objective of this phase I clinical trial was to establish pairwise similarity between BAT1706, US-sourced BEV (US-BEV), and EU-sourced BEV (EU-BEV) after a single intravenous (IV) infusion in healthy male subjects.MethodsThis phase I clinical trial was a randomized, double-blinded, three-arm study in 128 healthy adult male subjects. Every subject received a single IV infusion of 1 mg/kg of study drug and was subsequently monitored for 14 weeks. Pharmacokinetic, safety, and immunogenicity data were collected from each patient. The primary pharmacokinetic endpoint of this clinical study was area under the concentration curve from time zero to infinity (AUC0–inf). Biosimilarity of the study drugs was confirmed if the two-sided 90% confidence interval (CI) ratios of the geometric means for the three pairwise comparisons were contained within the range 80–125%. Other pharmacokinetic parameters including area under the concentration curve to time t (AUC0–t), maximum concentration of drug in plasma (Cmax), half-life (t½), and time to Cmax (tmax) were also measured.ResultsThe pharmacokinetic parameters were comparable for the three drug products evaluated. The 90% CI for the AUC0–inf was 99–112% for BAT1706 versus EU-BEV, 97–110% for BAT1706 vs US-BEV and 92–104% for EU-BEV versus US-BEV comparisons, respectively, demonstrating biosimilarity. There were no significant adverse events attributable to BAT1706, as compared to EU-BEV and US-BEV. BAT1706 demonstrated a similar safety profile to EU-BEV and US-BEV. In addition, no anti-drug antibody positive result was reported for any subject included in the study.ConclusionIn this study, BAT1706, a proposed biosimilar of BEV, was shown to be highly similar to EU-BEV and US-BEV in terms of pharmacokinetic equivalence, safety, and immunogenicity in healthy subjects after a single IV infusion.Trial RegistrationNCT03030430.

Report this publication

Statistics

Seen <100 times